Keywords: novartis, zometa, offers, advance, bone, complications, kidney

Novartis' Zometa offers advance in bone complications of kidney cancer

Article | 24 March 2003

Swiss pharmaceutical major Novartis' bisphosphonate Zometa (zoledronicacid), already approved and marketed in over 60 countries including the USA for the prevention ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Novartis

Go to company listing

Related Drugs

zoledronic acid

Zometa

Go to drug listing